Summary
A number of insulin analogues have been developed by genetic engineering in order to improve the possibilities of substituting prandial and basal insulin requirements in diabetic patients by subcutaneous injection. For some short acting insulin analogues, in particular for [Lys(B28),Pro(B29)]-human insulin, preclinical and clinical trials have been performed. Despite the favourable pharmacokinetic and pharmacodynamic characteristics of these short-acting insulin analogues resulting in an attenuation of prandial hyperglycaemia following subcutaneous injection in diabetic patents, up to now, actual clinical benefits have not become apparent when they were used in clinical trials. [Diabetologia (1997) 40: S 91–S 97]
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berger, M., Heinemann, L. Are presently available insulin analogues clinically beneficial?. Diabetologia 40 (Suppl 2), S91–S96 (1997). https://doi.org/10.1007/s001250051416
Issue Date:
DOI: https://doi.org/10.1007/s001250051416